Potent and selective TAK1/MAP3K7 kinase inhibitor
Takinib is a potent and selective TAK1/MAP3K7 kinase inhibitor (IC50 = 8.2-9.5 nM). Selective for TAK1 over IRAK4, IRAK1, GCK, CLK2 and MINK1 (IC50 values = 120, 390, 430, 430 and 1900 nM, respectively). Demonstrates weak inhibition at Src and Yes1. Exhibits no inhibition of MAP2K or other MAP3K family members. Induces apoptosis following TNF-α stimulation in
in vitro
models of rheumatoid arthritis and metastatic breast cancer.
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-126046 |
| Réf. fabricant | 18708756 |
| Nom chimique ou matériau | N1-(1-Propyl-1 H-benzimidazol-2-yl)-1,3-benzenedicarboxamide |
| CAS | 1111556-37-6 |
| Quantité | 25 mg |
| Cible | Other Kinase Inhibitors |
| Formule moléculaire | C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> |
| Pureté | 0.98 |
